These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. A Diverse Set of Single-domain Antibodies (VHHs) against the Anthrax Toxin Lethal and Edema Factors Provides a Basis for Construction of a Bispecific Agent That Protects against Anthrax Infection. Vrentas CE; Moayeri M; Keefer AB; Greaney AJ; Tremblay J; O'Mard D; Leppla SH; Shoemaker CB J Biol Chem; 2016 Oct; 291(41):21596-21606. PubMed ID: 27539858 [TBL] [Abstract][Full Text] [Related]
27. Lethal and edema toxins in the pathogenesis of Bacillus anthracis septic shock: implications for therapy. Sherer K; Li Y; Cui X; Eichacker PQ Am J Respir Crit Care Med; 2007 Feb; 175(3):211-21. PubMed ID: 17095744 [TBL] [Abstract][Full Text] [Related]
29. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Albrecht MT; Li H; Williamson ED; LeButt CS; Flick-Smith HC; Quinn CP; Westra H; Galloway D; Mateczun A; Goldman S; Groen H; Baillie LW Infect Immun; 2007 Nov; 75(11):5425-33. PubMed ID: 17646360 [TBL] [Abstract][Full Text] [Related]
30. Efficacy assessment of a triple anthrax chimeric antigen as a vaccine candidate in guinea pigs: challenge test with Abdous M; Hasannia S; Salmanian AH; Arab SS Immunopharmacol Immunotoxicol; 2021 Aug; 43(4):495-502. PubMed ID: 34259590 [TBL] [Abstract][Full Text] [Related]
31. Antibodies against anthrax: mechanisms of action and clinical applications. Froude JW; Thullier P; Pelat T Toxins (Basel); 2011 Nov; 3(11):1433-52. PubMed ID: 22174979 [TBL] [Abstract][Full Text] [Related]
32. A new triple chimeric protein as a high immunogenic antigen against anthrax toxins: theoretical and experimental analyses. Abdous M; Hasannia S; Salmanian AH; Shahryar Arab S; Shali A; Alizadeh GA; Hajizadeh A; Khafri A; Mohseni A Immunopharmacol Immunotoxicol; 2019 Feb; 41(1):25-31. PubMed ID: 30621469 [No Abstract] [Full Text] [Related]
33. Toxins of Bacillus anthracis. Brossier F; Mock M Toxicon; 2001 Nov; 39(11):1747-55. PubMed ID: 11595637 [TBL] [Abstract][Full Text] [Related]
34. Rapid lethal effect in rats of a third component found upon fractionating the toxin of Bacillus anthracis. BEALL FA; TAYLOR MJ; THORNE CB J Bacteriol; 1962 Jun; 83(6):1274-80. PubMed ID: 13866126 [TBL] [Abstract][Full Text] [Related]
36. Very Early Blood Diffusion of the Active Lethal and Edema Factors of Bacillus anthracis After Intranasal Infection. Rougeaux C; Becher F; Goossens PL; Tournier JN J Infect Dis; 2020 Feb; 221(4):660-667. PubMed ID: 31574153 [TBL] [Abstract][Full Text] [Related]
37. Radiolabeled antibodies to Bacillus anthracis toxins are bactericidal and partially therapeutic in experimental murine anthrax. Rivera J; Nakouzi AS; Morgenstern A; Bruchertseifer F; Dadachova E; Casadevall A Antimicrob Agents Chemother; 2009 Nov; 53(11):4860-8. PubMed ID: 19704133 [TBL] [Abstract][Full Text] [Related]
38. Differential detection of a surrogate biological threat agent (Bacillus globigii) with a portable surface plasmon resonance biosensor. Adducci BA; Gruszewski HA; Khatibi PA; Schmale DG Biosens Bioelectron; 2016 Apr; 78():160-166. PubMed ID: 26606307 [TBL] [Abstract][Full Text] [Related]
39. Pathogenicity, population genetics and dissemination of Bacillus anthracis. Pilo P; Frey J Infect Genet Evol; 2018 Oct; 64():115-125. PubMed ID: 29935338 [TBL] [Abstract][Full Text] [Related]
40. The structure and function of novel proteins of Bacillus anthracis and other spore-forming bacteria: development of novel prophylactic and therapeutic agents. Jedrzejas MJ Crit Rev Biochem Mol Biol; 2002; 37(5):339-73. PubMed ID: 12449428 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]